Advertisement
Singapore markets close in 7 hours 8 minutes

  • Straits Times Index

    3,295.27
    +29.32 (+0.90%)
     

  • Nikkei

    38,301.74
    +227.76 (+0.60%)
     

  • Hang Seng

    18,745.02
    +207.21 (+1.12%)
     

  • FTSE 100

    8,381.35
    +27.30 (+0.33%)
     

  • Bitcoin USD

    62,819.11
    +1,352.43 (+2.20%)
     

  • CMC Crypto 200

    1,351.88
    +51.78 (+3.98%)
     

  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     

  • Dow

    39,387.76
    +331.36 (+0.85%)
     

  • Nasdaq

    16,346.26
    +43.46 (+0.27%)
     

  • Gold

    2,358.50
    +18.20 (+0.78%)
     

  • Crude Oil

    79.80
    +0.54 (+0.68%)
     

  • 10-Yr Bond

    4.4490
    -0.0430 (-0.96%)
     

  • FTSE Bursa Malaysia

    1,601.48
    +0.26 (+0.02%)
     

  • Jakarta Composite Index

    7,088.79
    -34.81 (-0.49%)
     

  • PSE Index

    6,595.32
    +52.86 (+0.81%)
     

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines, Inc.
·2-min read
Revolution Medicines, Inc.
Revolution Medicines, Inc.

REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum.

Details of the company’s participation are as follows:

  • 23rd Annual Needham Healthcare Conference
    Conference Dates: April 8-11, 2024
    Fireside Chat Time/Date: 1:30 – 2:10 p.m. ET on Thursday, April 11, 2024
    Location: Virtual; webcast available

ADVERTISEMENT

  • Stifel Targeted Oncology Forum
    Conference Dates: April 16-17, 2024
    Fireside Chat Time/Date: 3:30 – 3:55 p.m. ET on Tuesday, April 16, 2024
    Location: Virtual; webcast available

To access the live webcasts of the Needham and Stifel fireside chats, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of each webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).

CONTACT: Media & Investor Contact Erin Graves 650-779-0136 egraves@revmed.com